eli lilly stock retatrutide shares safety, tolerability data on its next-gen obesity drug Eli Lilly Hit a 52-Week

Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity

For example, the STEP 1 trial of once-weekly semaglutide (2.4 mg) in people without diabetes achieved a ~15% average body weight reduction over 68 weeks (source), with a mean baseline BMI of ~38 (source)

But gastric sleeve may be the better choice if: Your BMI qualifies you for bariatric surgery You want a a more durable tool You have significant obesity-related medical problems You are tired of the recurring cost of GLP-1 drugs You do not want to rely on indefinite injections You have lost and regained weight repeatedly on diets or medication You want a treatment with a stronger long-term track record For many patients with obesity, gastric sleeve is not a last resort. It is simply the most logical long-term treatment

The safe point is simple: never trade injection comfort for temperature abuse